HER2-positive breast cancer samples showed a distinctly higher Gal-7 expression in the cytoplasm compared to HER2-negative tumor sections (median IRS in HER2+: 8 vs. in HER2-: 4, p < 0.001, Figure 3e). This evidence concerns the gene IARS1 and breast carcinoma.